Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
Passage Bio (NASDAQ: PASG), a clinical stage genetic medicines company specializing in neurodegenerative diseases, has announced its participation in the upcoming Guggenheim Securities Healthcare Innovation Conference. Will Chou, M.D., the company's president and CEO, will deliver a presentation on November 13, 2024, at 2:30 p.m. ET. The presentation will be accessible via live webcast on the company's investor relations website, with a replay available for 30 days after the event.
Passage Bio (NASDAQ: PASG), un'azienda in fase clinica specializzata in terapie geniche per malattie neurodegenerative, ha annunciato la sua partecipazione alla prossima Guggenheim Securities Healthcare Innovation Conference. Will Chou, M.D., presidente e CEO dell'azienda, terrà una presentazione il 13 novembre 2024, alle 14:30 ET. La presentazione sarà accessibile tramite webcast in diretta sul sito web delle relazioni con gli investitori dell'azienda, con una replica disponibile per 30 giorni dopo l'evento.
Passage Bio (NASDAQ: PASG), una empresa en etapa clínica especializada en medicamentos genéticos para enfermedades neurodegenerativas, ha anunciado su participación en la próxima Guggenheim Securities Healthcare Innovation Conference. Will Chou, M.D., presidente y CEO de la empresa, ofrecerá una presentación el 13 de noviembre de 2024, a las 2:30 p.m. ET. La presentación estará disponible a través de una transmisión en vivo en el sitio web de relaciones con inversionistas de la empresa, con una repetición disponible durante 30 días después del evento.
Passage Bio (NASDAQ: PASG)는 신경퇴행성 질환을 전문으로 하는 임상 단계 유전자 치료 회사로, 다가오는 Guggenheim Securities Healthcare Innovation Conference에 참여한다고 발표했습니다. Will Chou, M.D.인 회장 겸 CEO가 2024년 11월 13일 오후 2시 30분 ET에 프레젠테이션을 진행할 예정입니다. 프레젠테이션은 회사의 투자자 관계 웹사이트를 통해 실시간 웹캐스트로 접근 가능하며, 이벤트 이후 30일 동안 재방송이 가능합니다.
Passage Bio (NASDAQ: PASG), une entreprise de biotechnologie en phase clinique spécialisée dans les médicaments génétiques pour les maladies neurodégénératives, a annoncé sa participation à la prochaine Guggenheim Securities Healthcare Innovation Conference. Will Chou, M.D., le président et PDG de l'entreprise, fera une présentation le 13 novembre 2024 à 14h30 ET. La présentation sera accessible via un webcast en direct sur le site des relations investisseurs de l'entreprise, avec une rediffusion disponible pendant 30 jours après l'événement.
Passage Bio (NASDAQ: PASG), ein klinisches Unternehmen für genetische Medikamente, das auf neurodegenerative Erkrankungen spezialisiert ist, hat seine Teilnahme an der bevorstehenden Guggenheim Securities Healthcare Innovation Conference angekündigt. Will Chou, M.D., der Präsident und CEO des Unternehmens, wird am 13. November 2024 um 14:30 Uhr ET eine Präsentation halten. Die Präsentation wird über einen Live-Webcast auf der Website für Investor Relations des Unternehmens zugänglich sein, mit einer Wiederholung, die 30 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET.
A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com.
For further information, please contact:
Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com
Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com
FAQ
When is Passage Bio (PASG) presenting at the Guggenheim Securities Healthcare Conference 2024?
How can I watch Passage Bio's (PASG) Guggenheim Securities Conference presentation?
Who will represent Passage Bio (PASG) at the Guggenheim Securities Conference 2024?
How long will Passage Bio's (PASG) Guggenheim Securities Conference presentation be available for replay?
